{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:33:48Z","timestamp":1776987228791,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s00280-013-2342-3","type":"journal-article","created":{"date-parts":[[2013,11,12]],"date-time":"2013-11-12T13:52:40Z","timestamp":1384264360000},"page":"231-236","source":"Crossref","is-referenced-by-count":4,"title":["Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"M.","family":"Krzakowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Dansin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hiret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Penel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Favrel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Tourani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"2342_CR1","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/S0959-8049(98)00312-8","volume":"34","author":"ML Janssen-Heijnen","year":"1998","unstructured":"Janssen-Heijnen ML, Gatta G, Forman D, Capocaccia R, Coebergh JW et al (1998) Variation in survival of patients with lung cancer in Europe, 1985-1989. Eur J Cancer 34:2191\u20132196","journal-title":"Eur J Cancer"},{"key":"2342_CR2","doi-asserted-by":"crossref","unstructured":"Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel Members (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO consensus conference in lung cancer; Lugano 2010. Ann Oncol 22:1507\u20131519","DOI":"10.1093\/annonc\/mdr150"},{"key":"2342_CR3","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1200\/JCO.1997.15.9.3049","volume":"15","author":"WK Evans","year":"1997","unstructured":"Evans WK, Newman T, Graham I, Rusthoven JJ, Logan D et al (1997) Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group. J Clin Oncol 15:3049\u20133059","journal-title":"J Clin Oncol"},{"key":"2342_CR4","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/01243894-200611000-00021","volume":"1","author":"J Noble","year":"2006","unstructured":"Noble J, Ellis PM, Mackay JA, Evans WK et al (2006) Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 1:1042\u20131058","journal-title":"J Thorac Oncol"},{"key":"2342_CR5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"FA Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"2342_CR6","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1200\/JCO.2009.23.4146","volume":"28","author":"M Krzakowski","year":"2010","unstructured":"Krzakowski M, Ramlau R, Jassem J, Szczesna A, Zatloukal P et al (2010) Phase III trial comparing vinflunine with docetaxel in second-line advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy. J Clin Oncol 28:2167\u20132173","journal-title":"J Clin Oncol"},{"key":"2342_CR7","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/cncr.22616","volume":"109","author":"YM Chen","year":"2007","unstructured":"Chen YM, Liu JM, Chou TY, Perng RP, Tsai CM et al (2007) Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2\u00a0weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 109:1821\u20131828","journal-title":"Cancer"},{"key":"2342_CR8","first-page":"908","volume":"53","author":"S Lobert","year":"1998","unstructured":"Lobert S, Ingram JW, Hill BT, Correia JJ (1998) A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 53:908\u2013915","journal-title":"Mol Pharmacol"},{"key":"2342_CR9","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jchromb.2007.03.030","volume":"853","author":"G Zorza","year":"2007","unstructured":"Zorza G, Van Heugen JC, De Graeve J, Puozzo C et al (2007) Development of a sensitive liquid chromatography coupled with a tandem mass spectrometry detection for the clinical analysis of vinflunine and 4-O-deactylvinflunine in blood, urine and faeces. J Chrom B 853:294\u2013302","journal-title":"J Chrom B"},{"key":"2342_CR10","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1570-0232(03)00356-8","volume":"793","author":"M Zhao","year":"2003","unstructured":"Zhao M, He P, Rudek MA, Hildago M, Baker SD et al (2003) Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J Chrom B 793:413\u2013420","journal-title":"J Chrom B"},{"key":"2342_CR11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10637-007-9045-8","volume":"25","author":"AM Davies","year":"2007","unstructured":"Davies AM, Ho C, Hesketh PJ, Beckett LA, Lara PN Jr et al (2007) Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study. Invest New Drugs 25:351\u2013355","journal-title":"Invest New Drugs"},{"key":"2342_CR12","doi-asserted-by":"crossref","unstructured":"Scagliotti G, Rossi A, Novello S, De Marinis F, Dogliotti L et al (2004) Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 22:7081","DOI":"10.1200\/jco.2004.22.90140.7081"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2342-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2342-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2342-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T03:24:34Z","timestamp":1647055474000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2342-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["2342"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2342-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]}}}